Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureShuai Zhang, Yingying Huang, Xiang‐Yang Wang et al.|Research Square|2022Cited by 0